Citigroup
THRD

Citigroup’s Third Harmonic Bio THRD Stock Holding History

Citigroup’s Portfolio THRD Stock Details THRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-14,220
Closed -$77.2K – 6322
2025
Q2 		$77.2K Sell
14,220
-1,623
-10% -$8.09K ﹤0.01% 4543
2025
Q1 		$55K Sell
15,843
-4,469
-22% -$21.7K ﹤0.01% 4848
2024
Q4 		$209K Buy
20,312
+3,803
+23% +$47.4K ﹤0.01% 4386
2024
Q3 		$224K Buy
16,509
+11,045
+202% +$137K ﹤0.01% 4262
2024
Q2 		$71K Buy
5,464
+1,520
+39% +$18.8K ﹤0.01% 4391
2024
Q1 		$37.2K Buy
3,944
+367
+10% +$3.57K ﹤0.01% 4770
2023
Q4 		$39.2K Buy
3,577
+3,568
+39,644% +$28.3K ﹤0.01% 4650
2023
Q3 		$58 Sell
9
-5,792
-100% -$35.4K ﹤0.01% 5507
2023
Q2 		$27.9K Buy
+5,801
New +$27.6K ﹤0.01% 4871
2023
Q1 		– Sell
-414
Closed -$1.78K – 5855
2022
Q4 		$1.78K Buy
+414
New +$6.93K ﹤0.01% 5274

Other funds holding THRD

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CF
Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MIM
MetLife Investment Management Whippany, New Jersey $19.6B AUM 32.64% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AB
Amalgamated Bank New York $13.1B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Citigroup's THRD Position: Q3 2025 in Review

Citigroup sold out of Third Harmonic Bio (THRD) in Q3 2025, closing a stake of 14,220 shares — an estimated $77.2K sold.

Citigroup first reported a position in THRD in Q4 2022 and held it in 10 quarters. The position peaked at $224K in Q3 2024. 18 funds tracked by Wall St. Rank hold THRD as of Q3 2025.

  • Citigroup reported no remaining Third Harmonic Bio position as of Q3 2025 after selling out during the quarter.
  • Citigroup sold 14,220 Third Harmonic Bio shares in Q3 2025, an estimated $77.2K.
  • Citigroup first reported a position in Third Harmonic Bio in Q4 2022 and held it in 10 quarters.
  • Citigroup's Third Harmonic Bio position peaked at $224K in Q3 2024.
  • 18 funds tracked by Wall St. Rank held Third Harmonic Bio as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.